Please login to the form below

Not currently logged in
Email:
Password:

Cardioxyl appoints Novartis scientist as chief medical officer

Shi Yin Foo joins cardiovascular specialist

Cardioxyl Shi Yin Foo Cardioxyl Pharmaceuticals has appointed Novartis' Dr Shi Yin Foo as chief medical officer.

Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at US-based cardiovascular specialist Cardioxyl.

This experience includes time as a clinical and translational medicine reviewer for numerous studies from phase I to phase III clinical trials.

“Her unique combination of both early- and late-stage cardiovascular development experience combined with her extensive clinical experience in the treatment of patients with heart failure will serve as an excellent complement to Cardioxyl's proprietary expertise in the biology, physiology and chemistry of nitroxyl donors," said Dr Chris Kroeger, Cardioxyl's president and CEO.

Dr Foo spent four years at Novartis from 2009 have joined the pharma company from her role as a physician at Massachusetts General Hospital in the US, where she specialised in cardiology.

16th September 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics